In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SSP Co. Ltd.

Division of Boehringer Ingelheim GmbH
www.ssp.co.jp

Latest From SSP Co. Ltd.

Boehringer Ingelheim To Close Early Research Department In Japan

Boehringer Ingelheim’s Kobe Pharma Research Institute will continue to operate, but is expected to be stripped of its molecular and cellular biology capabilities.

BioPharmaceutical Japan

Biopharma Quarterly Statistics Q1 2010

In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.
BioPharmaceutical

Japan: The Final Frontier

Most western drug firms have shunned the Japanese market, regarded as highly problematic. But short on new products and with diminishing returns on investment at home, many are now taking a fresh look at the world's second largest health care market.
BioPharmaceutical North America

Arena Pharmaceuticals Inc.

Arena Pharmaceuticals has a new paradigm for drug discovery. It can discover small molecule drugs that act at a receptor without first finding the receptor's natural ligand.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • SS Pharmaceutical Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Boehringer Ingelheim GmbH
  • Senior Management
  • Seiichiro Hatori, Pres.
  • Contact Info
  • SSP Co. Ltd.
    Phone: (81) 3/ 3668 4511
    2-12-4, Nihombashi-Hamacho
    Chuo-ku
    Tokyo, 103-8481
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register